Pola-R-CHP Generates Long-Term PFS and DFS Advantages vs R-CHOP in Untreated DLBCL
Polatuzumab vedotin plus R-CHP improved PFS and DFS vs R-CHOP at 5 years in previously untreated patients with diffuse large B-cell lymphoma.
Related Articles
Novel regimen greatly reduced chronic GVHD in phase 2 study at Fred Hutch
A novel drug regimen tested for the first time by researchers at Fred Hutch Cancer Center has shown great promise in preventing moderate to severe…
FDA Grants Key Oncology Approvals and Designations in January 2025
Here is a look back on all the FDA happenings from the month of January 2025.
2024 Blood Journal Contest
9th Annual Blood Cover Art Contest is now open. In recognition of authors who published in Blood and images used in advancement of science, we…
Podcast: The Scope of US Medical Debt w/ Kinika Young | Health Affairs Podcast
Health Affairs’ Jeff Byers welcomes Kinika Young of The Leukemia & Lymphoma Society to the program to discuss a recent final rule/advisory issued by the…
January 2025 Early Career Newsletter – American Society for Radiation Oncology (ASTRO)
This issue includes important information on the committee’s initiatives for the upcoming year, including recording podcasts, organizing informal meetups at different society meetings, collaborating with…
Standard of care for frontline treatment of non-V600E-specific pLGG tumors
The experts in pediatric low-grade gliomas (pLGG) delineate the standard of care for frontline treatment of tumors not harboring the BRAF V600E mutation, outlining current…
Talquetamab Combo Data Warrant Further Research in R/R Multiple Myeloma
Findings from RedirecTT-1 show responses across different dose levels of talquetamab/teclistamab among those with multiple myeloma.
Podcast: The Scope of US Medical Debt w/ Kinika Young | Health Affairs Podcast
Health Affairs’ Jeff Byers welcomes Kinika Young of The Leukemia & Lymphoma Society to the program to discuss a recent final rule/advisory issued by the…